Tiziana's Phase 2a MSA Study Poster Accepted for Parkinson Congress

Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress. The poster will detail the design and rationale of the TILS-025 trial, which is the first clinical investigation of intranasal anti-CD3 therapy in MSA. This presentation highlights the company's progress in developing a potential treatment for a rapidly progressive neurodegenerative disorder with high unmet medical need.